Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)

Market Cap	8.38B
Revenue (ttm)	2.18B
Net Income (ttm)	526.33M
Shares Out	587.57M
EPS (ttm)	0.90
PE Ratio	15.85
Forward PE	16.59
Dividend	0.60 (4.19%)
Ex-Dividend Date	May 30, 2025

Volume	1,888,553
Average Volume	2,678,946
Open	14.42
Previous Close	14.33
Day's Range	14.19 - 14.42
52-Week Range	12.07 - 16.99
Beta	0.47
RSI	61.45
Earnings Date	Aug 26, 2025

About SHE:002275

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China. The company primarily offers Guilin watermelon frost and lozenge, and Sanjin tablets under the Chinese TCM brand; and Naomaitai capsules, etc. It also produces TCM preparations. Guilin Sanjin Pharmaceutical Co., Ltd. was founded in 1967 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,567
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002275

Financial Performance

In 2024, SHE:002275's revenue was 2.19 billion, an increase of 1.03% compared to the previous year's 2.17 billion. Earnings were 521.53 million, an increase of 23.79%.